Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 4 Carcinoid Tumor 3 Pheochromocytoma 1 Paraganglioma 1 Neoplasm Metastasis 1 Gastrointestinal Neoplasms 1 Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 9 avelumab 9 Nivolumab 8 atezolizumab 4 Specimen Handling 4 durvalumab 3 cemiplimab 3 Radiotherapy 3 Magnetic Resonance Spectroscopy 3 Etoposide 3 Cyclophosphamide 3 Biopsy 3 ALT-803 3 talimogene laherparepvec 2 fludarabine phosphate 2 fludarabine 2 domatinostat 2 Radiosurgery 2 Ipilimumab 2 Cisplatin 2 Carboplatin 2 relatlimab 1 oblimersen 1 lutetium Lu 177 dotatate 1 lenvatinib 1 lanreotide 1 daromun 1 cabozantinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Merkel Cell × lanreotide × Clear all

NCT02351128 2017-10-18

PHRC-Merkel

University Hospital, Grenoble

Phase 2 Completed

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡